Biotech developing in vivo CAR-T cell therapies. Acquired by AbbVie for $2.1B upfront in 2024.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
